Wall Street brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce $33.63 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The highest sales estimate is $37.20 million and the lowest is $30.00 million. Heron Therapeutics posted sales of $19.79 million in the same quarter last year, which suggests a positive year-over-year growth rate of 69.9%. The firm is scheduled to report its next earnings report on Wednesday, November 6th.
According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $130.42 million for the current fiscal year, with estimates ranging from $124.00 million to $139.30 million. For the next year, analysts anticipate that the firm will report sales of $197.38 million, with estimates ranging from $150.00 million to $253.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The firm had revenue of $36.66 million during the quarter, compared to the consensus estimate of $31.04 million.
Several brokerages have recently weighed in on HRTX. Evercore ISI reaffirmed a “buy” rating and issued a $75.00 target price on shares of Heron Therapeutics in a research report on Tuesday, August 13th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $52.67.
Large investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Heron Therapeutics in the fourth quarter worth about $13,679,000. Boston Advisors LLC lifted its stake in shares of Heron Therapeutics by 443.9% in the first quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock worth $3,288,000 after acquiring an additional 109,819 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Heron Therapeutics by 6.5% in the fourth quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock worth $716,000 after acquiring an additional 1,679 shares in the last quarter. Virginia Retirement Systems ET AL lifted its stake in shares of Heron Therapeutics by 2.3% in the first quarter. Virginia Retirement Systems ET AL now owns 36,100 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 800 shares in the last quarter. Finally, Pier Capital LLC lifted its stake in shares of Heron Therapeutics by 6.3% in the first quarter. Pier Capital LLC now owns 269,514 shares of the biotechnology company’s stock worth $6,587,000 after acquiring an additional 15,914 shares in the last quarter.
Shares of NASDAQ HRTX traded down $0.71 on Friday, hitting $17.38. The company had a trading volume of 441,401 shares, compared to its average volume of 861,797. Heron Therapeutics has a 12-month low of $15.68 and a 12-month high of $41.10. The business has a 50 day moving average of $17.86 and a two-hundred day moving average of $21.15. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.44 billion, a P/E ratio of -7.12 and a beta of 1.49.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Article: What is Green Investing?
Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.